The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector

Oncology Reports

Volumn 21, Issue 5, 2009, Pages 1335-1343

  Zurkova, K ^a   Babiarova, K ^a   Hainz, P ^a   Krystofova, J ^a   Kutinova, L ^a   Otahal, P ^b   Nemeckova, Sarka ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Antibodies; CTL; HPV16 E7; Immune response; Soluble Flt3 ligand; Vaccinia virus

Indexed keywords

CD11B ANTIGEN; FLT3 LIGAND; GLYCOPROTEIN P 15095; PROTEIN E6; PROTEIN E7; VACCINIA VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DNA REPLICATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SUPPRESSOR CELL; TUMOR IMMUNITY; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS; TRANSFECTION; VACCINIA VIRUS;

EID: 67649385980     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000359     Document Type: Article

References (24)

1. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D and Hwang TH: Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370, 2006.
2. Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC and Zajac P: Non-replicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum Gene Ther 16: 348-360, 2005.
3. Chavan R, Marfatia KA, An IC, Garber DA and Feinberg MB: Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 80: 7676-7687, 2006.
4. Flanagan K, Glover RT, Horig H, Yang W and Kaufman HL: Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T cell dependent antitumor response. Vaccine 22: 2894-2903, 2004.
5. Suss G and Shortman K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 183: 1789-1796, 1996.
6. Pulendran B, Smith JL, Jenkins M, Schoenborn M, Maraskovsky E and Maliszewski CR: Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med 188: 2075-2082, 1998.
7. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE and Schuh JC: Flt3 ligand induces tumor regression and anti-tumor immune responses in vivo. Nat Med 3: 625-631, 1997.
8. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E and Zitvogel L: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5: 405-411, 1999.
9. zurHausen H: Papillomaviruses in human cancers. Proc Assoc Am Physicians 111: 581-587, 1999.
10. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC and Stern PL: Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 63: 6032-6041, 2003.
11. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA and Sterling JC: Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9: 5205-5213, 2003.
12. Kutinova L, Ludvikova V, Simonova V, Otavova M, Krystofova J, Hainz P, Press M, Kunke D and Vonka V: Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine 13: 487-493, 1995.
13. Nemeckova S, Stranska R, Subrtova J, Kutinova L, Otahal P, Hainz P, Maresova L, Sroller V, Hamsikova E and Vonka V: Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface. Cancer Immunol Immunother 51: 111-119, 2002.
14. Perkus ME, Panicali D, Mercer S and Paoletti E: Insertion and deletion mutants of vaccinia virus. Virology 152: 285-297, 1986.
15. Mackova J, Kutinova L, Hainz P, Krystofova J, Sroller V, Otahal P, Gabriel P and Nemeckova S: Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol 24: 1581-1588, 2004.
16. Kutinova L, Nemeckova S, Hamsikova E, Zavadova H, Ludvikova V, Broucek J, Kunke D, Konig J, Zakharova LG and Pashvykina GV: Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells. Arch Virol 134: 1-15, 1994.
17. Joklik WK: The purification of four strains of poxvirus. Virology 18: 9-18, 1962.
18. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
19. Michl J: Metabolism of cells in tissue culture in vitro. I. The influence of serum protein fractions on the growth of normal and neoplastic cells. Exp Cell Res 23: 324-330, 1961.
20. Hamsikova E, Zavadova H, Kutinova L, Ludvikova V, Krchnak V, Nemeckova S and Vonka V: Priming effect of recombinant vaccinia virus coding for the middle hepatitis B surface antigen. Arch Virol 113: 283-289, 1990.
21. Nemeckova S, Sroller V, Hainz P, Krystofova J, Smahel M and Kutinova L: Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice. Int J Mol Med 12: 789-796, 2003.
22. Gherardi MM, Ramirez JC, Rodriguez D, Rodriguez JR, Sano G, Zavala F and Esteban M: IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 162: 6724-6733, 1999.
23. Parajuli P, Mosley RL, Pisarev V, Chavez J, Ulrich A, Varney M, Singh RK and Talmadge JE: Flt3 ligand and granulocytemacrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 29: 1185-1193, 2001.
24. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA and Restifo NP: Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 161: 5313-5320, 1998.